HomeAI · summaries
Storia in 5 fonti
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured more chatter on obesity drugs and pipeline programs than those spec | Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
- ·
markets.businessinsider.com
Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story
Eli Lilly and Company (LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental d...
